Company: SNSE
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0000950170-25-053033
Chunk: 17

Company: Sensei Biotherapeutics, Inc.
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 17
---
 management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements. Our Nominating and Corporate Governance Committee monitors the effectiveness of our corporate governance guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the Board as quickly as possible. The Board Chairman coordinates between the Board and management with regard to the determination and implementation of responses to any problematic risk management issues.

MEETINGS OF THE BOARD OF DIRECTORS

<div align='center'>9</div>

The Board of Directors met six times during the last fiscal year. Each Board member attended 75% or more of the aggregate number of meetings of the Board and of the audit, compensation and nominating and corporate governance committees on which he or she served, held during the portion of the last fiscal year for which he or she was a director or committee member. As required under applicable Nasdaq listing standards, during the last fiscal year, the Company’s independent directors met four times in regularly scheduled executive sessions at which only independent directors were present. INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS The Board has three committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and the number of meetings for the year ended December 31, 2024 for each of the Board committees:

|                            |     | Audit Committee |   |     |   |     | Compensation 
 Committee    |   |     |   |     | Nominating and 
 Corporate      
 Governance     
 Committee      |   |     |   |
| John Celebi                |     |                 |   |     |   |     |              |   |     |   |     |                |   |     |   |
| William Ringo (1)          |     |                 |   |     |   |     | X            |   |     |   |     | X              |   |     | * |
| Bob Holmen                 |     | X               |   |     |   |     | X            |   |     | * |     |                |   |     |   |
| James Peyer, Ph.D.         |     |                 |   |     |   |     | X            |   |     |   |     | X              |   |     |